Study of A166 for advanced HER2-positive breast cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called A166 for people with HER2-positive breast cancer that has spread or can't be removed. It is for those who have already tried up to five treatments, including a specific type of HER2 antibody-drug conjugate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been diagnosed with breast cancer that is advanced or has spread to other parts of the body.
- You have had no more than 5 different treatments for advanced disease, and at least one included a HER2 antibody-drug conjugate with a topoisomerase inhibitor.
- Your cancer has worsened or you could not tolerate your most recent treatment.
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SHR-A1811 in patients with advanced breast cancer that has a protein called HER2. The drug may help slow or stop cancer growth in patients who haven't had too many prior treatments.
This trial tests a new drug, CAN016, for people with advanced solid tumors that have HER2 expression or a HER2 gene change. You may qualify if your cancer has gotten worse after trying other HER2-targeted treatments.
This trial tests two new antibody-based drugs (trastuzumab rezetecan and trastuzumab deruxtecan) designed to treat advanced breast cancer that has spread or cannot be removed with surgery. These drugs target HER2, a protein found on certain cancer cells, and may help patients whose cancer has progressed after previous treatment with trastuzumab and chemotherapy.
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
This study tests a new antibody-drug conjugate (FDA022-BB05) for people with advanced solid cancers—especially breast, endometrial, bladder, colorectal, or lung cancer—that have stopped responding to standard therapy. The drug targets HER2, a protein on some cancer cells, to try to shrink tumors or slow their growth.
This trial tests two new antibody drugs (SSGJ-705 and SSGJ-612), alone or combined with chemotherapy, in patients with advanced cancers that have a protein called HER2. The study aims to see if this combination can shrink tumors and help patients live longer.
Hear when a new HER-2 Positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.